Receptor IL
Os receptores de interleucina (receptores IL) são um grupo de receptores que se ligam às interleucinas, uma família de citocinas que desempenham papéis essenciais na regulação do sistema imunológico, inflamação e hematopoiese. A desregulação da sinalização de interleucina está associada a várias doenças inflamatórias e autoimunes, tornando os receptores IL alvos críticos para a intervenção terapêutica. Antagonistas dos receptores IL estão sendo explorados para o tratamento de condições como artrite reumatoide, psoríase e doenças inflamatórias intestinais. Na CymitQuimica, oferecemos uma gama de moduladores de receptores IL de alta qualidade para apoiar sua pesquisa em sinalização de citocinas, imunologia e terapia de doenças inflamatórias.
Foram encontrados 85 produtos de "Receptor IL"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
YQ128
CAS:YQ128 is a potent and selective inhibitor of second-generation NLRP3 (NOD-like receptor P3) inflammasome(IC50 of 0.30 µM), with anti-inflammatory activity.Fórmula:C27H29ClN2O4S2Pureza:99.89%Cor e Forma:SolidPeso molecular:545.11Ref: TM-T13375
1mg52,00€5mg113,00€10mg177,00€25mg289,00€50mg485,00€100mg700,00€1mL*10mM (DMSO)137,00€Vunakizumab
CAS:Vunakizumab is a humanized IgGκ monoclonal antibody targeting IL-17A, often linked to interleukin 22 to form Vunakizumab-IL22.Pureza:95%Cor e Forma:LiquidPeso molecular:146.38 kDaElsilimomab
CAS:Elsilimomab (B-E8) is a monoclonal antibody targeting IL-6, inhibiting the induction of bone marrow stromal cell senescence by dnmt3a mutation clones.Pureza:>95%Cor e Forma:LiquidPeso molecular:145.96 kDaIxekizumab
CAS:Ixekizumab: IgG4 antibody, neutralizes IL-17A (<3 pM), treats severe plaque psoriasis & arthritis.Pureza:98.86% (SEC-HPLC) - > 99.3% (SDS-PAGE); 95.4% (SEC-HPLC)Cor e Forma:LiquidPeso molecular:146.2 kDaSarilumab
CAS:Sarilumab: Potent IL-6 blocker, human antibody, reduces inflammation, treats rheumatoid arthritis.Pureza:97.4%Cor e Forma:LiquidPeso molecular:144.12 kDaPF-07038124 HCl
CAS:PF-07038124 HCl is a selective and potent PDE4 inhibitor with an IC50 of 0.5 nM for PDE4B2.PF-07038124 HCl inhibits IL-13, IL-4, and IFNγ, and can be used in the study of skin disorders such as atopic dermatitis and plaque psoriasis.Fórmula:C18H23BClNO4Pureza:97.34% - 99.13%Cor e Forma:SoildPeso molecular:363.64Bermekimab
CAS:Bermekimab (MABp1), an anti-interleukin-1α (IL-1α) monoclonal antibody.Bermekimab has potential anti-inflammatory activity to prevent skin inflammation.Cor e Forma:LiquidPeso molecular:145.45 kDaAnti-IL-6R Reference Antibody (Vobarilizumab-Fc)
CAS:Vobarilizumab (ALX-0061) is a humanized specific antibody targeting IL-6R and ALB, used in research on autoimmune diseases like rheumatoid arthritis.Pureza:>95%Cor e Forma:LiquidPeso molecular:78.2 kDaBriakinumab
CAS:Briakinumab (ABT-874) is a monoclonal antibody targeting IL-12, used in the research of psoriasis multiple sclerosis.Pureza:>95%Cor e Forma:LiquidPeso molecular:143.86 kDaNidanilimab
CAS:Nidanilimab (CAN04) is an IL1RAP antibody with 1.10 pM affinity and antitumor effects on NSCLC and PDAC.
Pureza:> 95%Cor e Forma:SoildPeso molecular:150 kDaSpesolimab
CAS:Spesolimab (BI 655130) is an antibody targeting IL-36 receptor, key in immunity, for systemic pustular psoriasis and dermatitis studies.Pureza:> 95%Cor e Forma:LiquidPeso molecular:150 kDaRisankizumab
CAS:Risankizumab (BI 655066) is a monoclonal antibody for psoriasis, targeting IL-23, with high affinity (Kd <10 pM) and an IC50 of 2 pM.Pureza:SDS-PAGE:95.3%;SEC-HPLC:98.3%Cor e Forma:LiquidPeso molecular:145.85 kDaSiltuximab
CAS:Siltuximab（CNTO-328） is a monoclonal antibody with anti-tumor activity targeting IL-6 for the study of giant lymph node hyperplasia (MCD) and COVID-19.Pureza:100% (SEC-HPLC) - > 95%Cor e Forma:LiquidPeso molecular:144.98 kDa2-Benzothiazolamine
CAS:2-ABT: nitrogen-rich heterocycle used in drug synthesis, inhibits P450, with anti-inflammatory, anticonvulsant, anticancer properties.Fórmula:C7H6N2SPureza:99.09% - 99.3%Cor e Forma:Plates From Water Physical Description Odorless Gray To White Powder (Ntp 1992)Peso molecular:150.2Brodalumab
CAS:Brodalumab (AMG 827), a human IgG2 monoclonal antibody, inhibits IL-17R, treating psoriasis.Pureza:98.3%Cor e Forma:LiquidPeso molecular:144.06 kDaEnokizumab
CAS:Enokizumab (MEDI-528) is a monoclonal antibody against interleukin IL-9. Enokizumab can be used to study asthma.
Pureza:SDS-PAGE:95% SEC-HPLC:99.23%Cor e Forma:LiquidPeso molecular:145.98 kDaIL-15-IN-1
CAS:IL-15-IN-1 is a selective and potent Interleukin 15 (IL-15) inhibitor, inhibiting the proliferation of IL-15-dependent cells (IC50: 0.8 μM).Fórmula:C30H36N6O4SPureza:99.16%Cor e Forma:SolidPeso molecular:576.71Ref: TM-T11634
1mg88,00€5mg170,00€10mg259,00€25mg429,00€50mg605,00€100mg815,00€200mg1.093,00€1mL*10mM (DMSO)210,00€Ordesekimab
CAS:Ordesekimab (AMG 714) is a human anti-IL-15 IgG1 κ monoclonal antibody for studying NRCD.Pureza:> 95%Cor e Forma:LiquidPeso molecular:145.12 kDaTildrakizumab
CAS:Tildrakizumab (SCH 900222) is a humanized antibody against IL-23, with a 136 pM Kd, used for psoriasis research.Pureza:> 95%Cor e Forma:LiquidPeso molecular:144.44 kDaTorudokimab
Torudokimab (ZB-880) is a monoclonal antibody that neutralizes interleukin 33 and can be used to study immune system diseases.Pureza:95.8% (SDS-PAGE); 96.2% (SEC-HPLC) - 95.8% (SDS-PAGE); 96.2% (SEC-HPLC)Cor e Forma:LiquidPeso molecular:144.71 kDa
